Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To investigate dosimetric impact of inter-observer variation in clinical target volume(CTV) delineation for patients undergoing interstitial partial breast brachytherapy.
Methods: Five radiation oncologists delineated CTV in twenty patients who underwent multi-catheter partial breast brachytherapy. Five treatment plans for each patient were graphically optimized for CTV of all observers and evaluated using coverage index(CI), external volume index(EI), overdose volume index(OI) and conformal index(COIN). In addition, volume enclosed by prescription isodose(V), its spatial concordance(CI), mean coverage of all CTVs with common volume of prescription dose(V) and mean CTV coverage for all pairs of observer with common prescription volume of respective pairs(V) were also computed.
Results: The mean ± standard deviation(SD) of CI and COIN ranged from 0.756 ± 0.076 to 0.840 ± 0.070 and 0.591 ± 0.090 to 0.673 ± 0.06 respectively. When a plan made for CTV of individual observer was evaluated on CTV of all observers, the maximum variations(ρ < 0.05) in the mean CI,COIN,OI and EI were 10.6%,11.4%,10.6% and 72.7% respectively. The observed mean ± SD of V, CI of V, CTV coverage with V and V was 160.7 ± 52.1, 0.70 ± 0.09, 73.1 ± 8.1% and 77.9 ± 7.3% respectively.
Conclusion: Inter-observer variation in delineation of CTV showed significant dosimetric impact with mean CTV coverage of 73.1% and 77.9% by common and paired prescription dose volume respectively among all observers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.radonc.2018.06.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in Patient-Reported Outcomes After Breast-Conserving Surgery and Partial-Breast Versus Whole-Breast Irradiation.
Ann Surg Oncol
September 2025
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Although several trials have demonstrated the oncologic safety of partial-breast irradiation (PBI) compared with whole-breast irradiation (WBI), data on patient-reported outcomes are mixed. Here we compare breast satisfaction and chest well-being using the BREAST-Q questionnaire among patients undergoing PBI versus WBI.
Patients And Methods: We identified patients undergoing lumpectomy and radiation, and analyzed their BREAST-Q scores preoperatively and postoperatively at 6 months, 1 year, 2 years, and 3 years.
The evolution of targeted intra operative radiotherapy in early breast cancer.
J Cancer Res Clin Oncol
September 2025
Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
Targeted intraoperative radiotherapy (IORT) delivers a single dose of radiation to a fresh tumour bed immediately after lumpectomy, commonly used to treat early breast cancer (EBC). It is delivered during the same sitting, with improved patient compliance and better sparing of adjacent healthy tissue, compared to conventional adjuvant radiotherapy to the whole breast. The recently published 12-year results (median follow up of 8.
View Article and Find Full Text PDFComplete Response to BET Inhibitor in Primary Pulmonary NUT Carcinoma With Single-Cell Sequencing-Based Analysis: A Case Report.
JTO Clin Res Rep
October 2025
Clinical Research Center (CRC), Medical Pathology Center (MPC), Cancer Early Detection and Treatment Center (CEDTC), and Translational Medicine Research Center (TMRC), Chongqing University Three Gorges Hospital, Wanzhou District, Chongqing, People's Republic of China.
NUT carcinoma is a rare and highly aggressive malignancy characterized by rapid progression, resistance to conventional therapies, and an extremely poor prognosis. This report presents a 36-year-old patient with stage IIIB primary pulmonary NUT carcinoma who achieved remarkable clinical outcomes with NHWD-870 monotherapy, a novel BET inhibitor. After just 1 month of treatment, imaging revealed a partial response, and a complete response was achieved within 5 months.
View Article and Find Full Text PDFSingle-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial.
J Vis Exp
August 2025
Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University; Key Laboratory of Chongqing Health Commission for Minimally Invasive and Precise Diagnosis and Treatment of Breast Cancer;
The integration of robotic platforms in breast oncology has witnessed substantial expansion, fueled by their inherent advantages in minimally invasive access and enhanced intraoperative maneuverability. Most of the robotic-assisted breast surgery has been performed using multi-arm robots. However, the implementation of single-port robotic (SPr) systems in mammary interventions continues to undergo rigorous clinical evaluation, particularly regarding long-term oncological safety and cost-effectiveness metrics.
View Article and Find Full Text PDFSafety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open-Label, Single-Arm, Phase IV Study.
Asia Pac J Clin Oncol
September 2025
Roche Products India Pvt. Ltd, Mumbai, India.
Introduction: Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, targets tumor cells overexpressing human epidermal growth factor receptor 2 (HER2). This single-arm, phase IV study assessed the safety and efficacy of T-DM1 in Indian patients with HER2-positive, locally advanced, or metastatic breast cancer previously treated with trastuzumab and a taxane.
Methods: Patients received T-DM1 (3.